Sinopharm modern holding company has obtained the overseas listing license for cefazolin sodium for injection.
On December 10, Sinopharm announced that its holding grandson Dali Pharma GmbH (hereinafter referred to as “Dali Pharma”) had received the marketing license of cefazolin sodium for injection (1g and 2G) approved and issued by the German federal agency for drugs and medical devices (bfarm).
Cefazolin sodium is the first generation of cephalosporin antibiotics. Clinically, it is generally used to treat bone and joint infection, skin and soft tissue infection caused by sensitive bacteria. It can also be used for perioperative prevention and reduce the incidence of postoperative infection.
Cefazolin sodium was the first generation cephalosporin developed by fujizawa Pharmaceutical Co., Ltd. of Japan. It was first listed in Japan in 1971 and approved by FDA in 1973. According to IMS data, the sales of the drug in the EU market in 2020 was US $45 million, and its main manufacturers were Teva, polpharma, hikma Pharma, etc.
After Dali Pharma’s cefazolin sodium for injection was submitted to the EU registered DCP process, it recently obtained the approval of the German federal agency for drugs and medical devices (bfarm) on the marketing license of 1G and 2G products. Up to now, the company has invested about 2.3 million yuan (Unaudited) in R & D expenses for cefazolin sodium for injection registered in EU.